Arachidonic acid epoxygenase and 12(S)-lipoxygenase: evidence of their concerted involvement in ductus arteriosus constriction to oxygen

Barbara Baragatti and Flavio Coceani

Abstract: Oxygen promotes closure of the ductus arteriosus at birth. We have previously presented a scheme for oxygen action with a cytochrome P450 (CYP450) hemoprotein and endothelin-1 (ET-1) being, respectively, sensor and effector, and a hypothetical monoxygenase product serving as a coupling link. We have also found in the vessel arachidonic acid (AA) 12(S)-lipoxygenase (12-lipoxygenase) undergoing upregulation at birth. Here, we examined the feasibility of a sensor-to-effector messenger originating from AA monoxygenase and 12-lipoxygenase pathways. The epoxygenase inhibitor, N-methylsulfonyl-6-(2)-hexanamide, suppressed the tonic contraction of ductus to oxygen. A similar effect was obtained with 12-lipoxygenase inhibitors baicailein and PD 146176. By contrast, none of the inhibitors modified the endothelin-1 contraction. Furthermore, an AA ω-hydroxylation product, 20-hydroxyeicosatetraenoic acid (20-HETE), reportedly responsible for oxygen contraction in the systemic microvasculature, had no such effect on the ductus. We conclude that AA epoxygenase and 12-lipoxygenase jointly produce a hitherto uncharacterized compound acting as oxygen messenger in the ductus.

Key words: ductus arteriosus, oxygen sensing, arachidonic acid epoxygenase, arachidonic acid lipoxygenase, arachidonic acid ω-hydroxylation, 20-hydroxyeicosatetraenoic acid, endothelin, fetal and neonatal physiology.

Introduction

The ductus arteriosus is a fetal shunt, connecting the pulmonary artery with the aorta, that closes shortly after birth coincidently with the natural rise in blood oxygen tension. Our previous studies have identified a cytochrome P450 (P450) hemoprotein of the 3A subfamily, specifically CYP3A13 in the mouse, as the prime oxygen sensor within ductal muscle and endothelin-1 (ET-1) as the ultimate effector for the contraction (Coceani 1999; Coceani et al. 1999; Coceani and Kelsey 2000; Baragatti et al. 2011). Still undefined, however, is the nature of the functional linkage between sensor and effector, although much evidence points to a CYP450-based monoxygenase reaction as the source of the putative messenger (Coceani et al. 1988; Coceani 1999). Knowing the importance of the eicosanoid system in the control of blood vessels, the ductus included (Smith 1998), we...
have attempted in the past to link the oxygen contraction of the ductus to an arachidonic acid (AA) epoxide (i.e., epoxyeicosatrienoic acid (EET)) but results have been negative (Cocceani et al. 1999). Lately, however, this system has acquired a greater degree of complexity with the characterization of a host of vasoactive agents, originating through epoxygenase- and lipoxygenase-based reactions (Pace-Asciak et al. 1999; Chen et al. 2008; Chawengsuk et al. 2009), and the realization of the potential for synthesis still being unfulfilled. Furthermore, a product of AA ω-hydroxylation, 20-hydroxyeicosatetraenoic acid (20-HETE), has been implicated in oxygen sensing of the systemic microvasculature (Kunert et al. 2001).

Application of this new knowledge to the mechanism of ductus closure has been limited or inconclusive. 20-HETE is seemingly not found in the ductus despite the presence of an appropriate CYP450 hemoprotein for its synthesis (Baragatti et al. 2001). Conversely, there is an active 12-lipoxygenase pathway, conceivably located in the muscle, whose function needs to be determined (Baragatti et al. 2009). Significantly, its initial enzyme, that is, 12/15-lipoxygenase (encoded by Alox15)1, is markedly upregulated in the neonatal ductus (Costa et al. 2006), as one would expect from any factor linked to the process of closure.

From this premise, the objective of the present study in the mouse ductus was twofold: (i) to assess the possible involvement of AA epoxygenase and 12-lipoxygenase in the oxygen activation sequence and (ii) to examine whether 20-HETE acts in its action with a role as oxygen mediator.

Materials and methods

Animals

Experiments were carried out with wild-type (WT) C57BL/6 mice (Harlan, San Pietro al Natisone, Italy) (litter size 1–12) and, in a few cases, with Cyp3a12–/– mice of the FVB strain (litter size 8–10) (courtesy of Dr. A.H. Schinkel; see van Herwaarden et al. 2007). In a previous study, it has been shown that the mutant lacks a critical isoform (i.e., CYP3A13) for oxygen sensing in the ductus (Baragatti et al. 2011). In addition, it has been confirmed that WT C57BL/6 and WT FVB strains share a similar response to oxygen in their fetal duct (Baragatti et al. 2011). Animals were housed in temperature- and humidity-controlled quarters, with constant 12 h light : 12 h dark cycles, and were given food and water ad libitum. Surgical procedures and experimental protocols were approved by the Animal Care Committee of the Ministry of Health (Rome, Italy).

Solutions and drugs

The Krebs medium had the following composition: 118 mol/L NaCl, 4.7 mol/L KCl, 2.5 mol/L CaCl₂, 1 mol/L KH₂PO₄, 0.9 mol/L MgSO₄, 11.1 mol/L dextrose, and 25 mol/L NaHCO₃. Solutions were bubbled with gas mixtures containing either no O₂ or O₂ in various concentrations (2.5%, 12.5%, 30%, and 95%), plus 5% CO₂ and balance N₂, with the intent of duplicating the fetal (2.5% O₂) and neonatal (from 12.5% O₂ upwards) conditions. For maximal contraction, oxygen is required at concentrations exceeding the physiological range (Cocceani et al. 1999), since a steep tissue gradient may occur even with a small-size vessel (Fay 1973).

PO₂ of the medium was measured with a Chiron gas analyzer (model 248, Chiron Diagnostics, Halstead, UK) and was 0.84 ± 0.01 kPa (n = 41), 2.15 ± 0.01 kPa (n = 41), 6.33 ± 0.19 kPa (n = 21), 20.7 ± 0.2 kPa (n = 21), and 82.5 ± 0.1 kPa (n = 21) (pH 7.410 ± 0.005; n = 41) with 0%, 2.5%, 12.5%, 30%, and 95% O₂ mixtures, respectively.

The following compounds were used: the suicide-substrate inhibitor of AA epoxidation, N-methylsulfonyl-6-(2-)hexanamide (MS-PPOH, courtesy of Dr. M. Schwartzman); the 12-lipoxygenase inhibitor baicalein (Sigma–Aldrich, St. Louis, Mo., USA), with a confirmed selective action in the ductus arteriosus (Baragatti et al. 2009); the 12/15-lipoxygenase inhibitor, 6,11-dihydro-5-thia-11-aza-benz[a]-fluorene (PD 146176) (Sendobry et al. 1997; DeCostanzo et al. 2010); 20-HETE (Cayman Chemical, Ann Arbor, Mich., USA); the thromboxane A₂ (TXA₂) analog 9,11-epithio-11,12-methano-TXA₂ (ONO-11113; courtesy of ONO Pharmaceutical, Osaka, Japan); the prostaglandin (PG) endoperoxide analog and TXA₂ mimic 9a,11a-epoxy-methano-15-hydroxy-prosta-5,13-dienoic acid (U-44069; Cayman Chemical); and endothelin-1 (ET-1; human–porcine type; Peninsula Laboratories, San Carlos, Calif., USA). Concentrations of the inhibitors were derived from the literature with the aim of combining efficacy with selectivity.

ONO-11113 and U-44069 were dissolved in distilled ethanol (respectively 5 and 0.1 mg/mL), and aliquots (stored at −70 °C) were diluted, respectively, with Tris buffer (pH 7.4) and saline. MS-PPOH, baicalein, and PD 146176 were also dissolved in ethanol (respectively 16.15, 1.35, and 2.37 mg/mL) before the final solution was prepared in Krebs medium. 20-HETE was first dissolved in ethanol (0.1 mg/mL), and then an appropriate aliquot was evaporated to near dryness under a stream of N₂ before being reacted with a stoichiometric amount of Na₂CO₃; the resulting product was prepared as a 100 µmol/L stock in Tris buffer (pH 9.0) to be ultimately diluted with Krebs medium as required. ET-1 was dissolved in sterile water with 0.05% human serum albumin (100 µmol/L), and aliquots of this stock solution were stored at −20 °C until use. Ethanol concentration in fluid bathing the ductus preparations did not exceed 0.01% (MS-PPOH), 0.2% (baicalein), 0.01% (PD 146176), 0.001% (ONO-11113), or 0.1% (U-44069). Ethanol vehicle has no significant effect at the given concentrations (Reese et al. 2009), and this was confirmed here. Solutions of baicalein were protected from light.

Concentrations of compounds are given in molar units and refer to their final value in Krebs medium.

In vitro recording

Term fetal mice, both WT and Cyp3a12–/– (gestational age 19 days), were delivered by cesarean section under halothane anesthesia and were killed by cervical dislocation. Body weight was 0.8–1.5 and 1.0–1.3 g, respectively, for WT and mutant, and only 1 fetus was used in each experiment. Procedures for ductus dissection, normalization of internal circumference, and mechanical record have been described (Cocceani et al. 1999). Briefly, the animal was secured with its left side

12/15-lipoxygenase manifests predominantly 12-lipoxygenase activity in rodents (Johannesson et al. 2010).
up in a dissection chamber containing ice-cold Krebs solution gassed with 5% CO2 in N2. Through thoracotomy, the ductus was exposed, separated from adjoining blood vessels, and suspended onto 25 µm tungsten wires (Cooner Wire Company, Chatsworth, N.J., USA) inside an organ bath. Fluid was gassed with a mixture containing 2.5% O2, and the same gas mixture was flushed through a hood covering the bath. Preparations were then equilibrated (about 60 min at 37 °C) under minimal stretch (WT: 0.046 ± 0.001 mN/mm; n = 38) (Cyp3a-/-: 0.048 ± 0.001 mN/mm; n = 3), and the attendant internal circumference (C0) with related resting dimension (WT: vessel length, long side: 567 ± 13 µm; vessel length, short side: 554 ± 13 µm; internal diameter: 134 ± 1 µm; wall thickness: 20 ± 0.3 µm; n = 38) (Cyp3a-/-: vessel length, long side: 533 ± 18 µm; vessel length, short side: 518 ± 15 µm; internal diameter: 134 ± 2 µm; wall thickness: 19 ± 1 µm; n = 3) served as a reference for choosing the appropriate load. Afterwards, tension was applied to attain an operating circumference (i.e., C50) coinciding with the condition in vivo (WT: 0.460 ± 0.005 mN/mm; n = 38) (Cyp3a-/-: 0.460 ± 0.009 mN/mm; n = 3). The actual experiment was started after a second equilibration of 60–120 min.

The study comprised 2 groups of experiments dealing, respectively, with the action of inhibitors of AA epoxygenase and 12-lipoxygenase on oxygen-induced contraction and with the response of the ductus to 20-HETE. In group 1 (n = 35), oxygen action was examined over a range of concentrations (12.5%, 30%, 95%) in the absence and presence of MS-PPOH (5 µmol/L), baicalein (10 µmol/L), or PD 146176 (1 µmol/L). Inhibitors were tested comparatively on the ductus contraction with ET-1 in view of the role being assigned to this compound as the ultimate effector in the oxygen activation sequence (Coceani 1999; Coceani et al. 1999;
Baragatti et al. 2011). ET-1 was applied to the organ bath in cumulative concentrations (0.1–300 nmol/L), using 3- to 10-fold increments. In group 2 (n = 6), 20-HETE action was studied comparatively in WT and Cyp3a<sup>−/−</sup> preparations, expecting that for the sake of compensation a messenger function of the compound may be magnified in the mutant. 20-HETE was tested cumulatively in 10-fold increments (1 µmol/L−1 µmol/L). In either protocol, ONO-11113 (0.1 µmol/L) and, in some experiments, U-44069 (0.3 µmol/L) provided a reference for maximal contraction. For analysis of responses, baseline was taken as the net tension (i.e., total tension minus applied tension) developed by the preparation before any treatment. Any response to tests was measured by the change in tension relative to baseline and was expressed in absolute values.

### Statistical analysis

Data are presented as means ± SE. Comparisons were made using Student’s t tests or two-way ANOVA followed by the Bonferroni test (SPSS program for Windows 10; SPSS, Inc., Chicago, Ill., USA). Differences were considered significant at p < 0.05.

### Results

As previously reported (Baragatti et al. 2011), the WT ductus developed a variable degree of tension during equilibration at 2.5% O<sub>2</sub> (0.067 ± 0.018 mN/mm, n = 38) and, once stabilized, contracted to oxygen in a concentration-dependent manner (Figs. 1a, 1c). ET-1 was also a constrictor from about 0.1 to 30 nmol/L, but the response in part subsided beyond that range (Figs. 1b, 1d). Transient contractions of uneven amplitude (0.1–0.7 mN/mm) and (or) low-amplitude exchanges were superimposed on the baseline and tended to increase during exposure to either agent. Unlike WT, the Cyp3a<sup>−/−</sup> ductus developed little or no tone at rest (see Baragatti et al. 2011), but its baseline still presented fast activity in 2 of 3 experiments. All preparations, whether WT or Cyp3a<sup>−/−</sup>, contracted to reference spasmodgens ONO-11113 (0.1 µmol/L; WT: 1.08 ± 0.07 mN/mm; n = 12) and U-44069 (0.3 µmol/L; WT: 0.86 ± 0.09; Cyp3a<sup>−/−</sup>: 1.00 ± 0.04 mN/mm; n = 3 for both).

The AA epoxygenase inhibitor MS-PPOH (5 µmol/L) had no effect on basal tension, but completely inhibited the tonic contraction to oxygen over its entire range of concentrations (Fig. 1a). In fact, the contraction was replaced by a relaxation in 2 experiments and, moreover, in one of them the response was concentration dependent. However, transient changes in tension, whether slow or fast in character, persisted throughout treatment. Contrary to its effect on oxygen, MS-PPOH did not alter the contractile response to either ET-1 (Fig. 1b) or ONO-11113 (1.01 ± 0.08 mN/mm; n = 7).

The AA 12-lipoxygenase inhibitors baicalein (10 µmol/L) and PD 146176 (1 µmol/L) contracted the resting ductus in all cases (baicalein: 0.43 ± 0.07 mN/mm, n = 8; PD 146176: 0.31 ± 0.05 mN/mm, n = 4). No further increase in tone occurred in baicalein-treated preparations upon exposure to oxygen but, on the contrary, the original contraction was replaced by a concentration-dependent relaxation (Fig. 1c). Also curtailed was the oxygen response during treatment with PD 146176, although to a lesser degree compared with the response to baicalein (Fig. 1c). Conversely, ET-1 action was not affected by baicalein, the modest shift rightward of the concentration–response curve being insignificant (Fig. 1d).

Likewise, ONO-11113 elicited a full-fledged contraction in the presence of either inhibitor (baicalein: 1.02 ± 0.05 mN/mm, n = 8; PD 146176: 0.85 ± 0.19 mN/mm, n = 4).

At variance with findings in the systemic circulation (Kunert et al. 2001), 20-HETE did not contract the ductus but instead produced a modest relaxation (Fig. 2). No difference in the pattern of the response was noted between WT and Cyp3a<sup>−/−</sup> preparations (Fig. 2).

### Discussion

Our study accords with the concept of a CYP450 hemoprotein serving as sensor in the ductus constriction to oxygen and, moreover, links its operation with an AA-based epoxygenase reaction. Critical to our conclusion is the outcome of tests with MS-PPOH. In fact, by curtailing the tonic but not the phasic component of the oxygen response, this inhibitor mimicked in full the behaviour of the ductus lacking the sensor hemoprotein (i.e., CYP3A13; see Baragatti et al. 2011). Furthermore, considering the specificity of MS-PPOH as AA epoxygenase inhibitor (Wang et al. 1998), the same data argue against any involvement of a CYP450-based, AA ω-hydroxylation reaction. This assumption is also strengthened by the negative results with 20-HETE, which according to current knowledge would be the prime candidate as oxygen mediator among the hydroxylation products (Kunert et al.
2001). Quite unexpectedly, it was also found that the oxygen response is curtailed by treatment with a 12-lipoxygenase inhibitor. This finding, while providing a possible meaning to the marked upregulation of this enzyme in the neonatal ductus (Costa et al. 2006), raises the prospect of the putative oxygen messenger originating from the combined activity of AA epoxygenase and 12-lipoxygenase pathways. Our discussion will address this possibility.

Among AA lipoxygenases, 12-lipoxygenase is in principle well suited to a messenger role. Several data, for example, implicate this pathway in synaptic function (DeCostanzo et al. 2010). In addition, the initial metabolite (i.e., hydroperoxy product) in this and the allied 15-lipoxygenase pathways yields diverse active products (Pace-Asciak et al. 1999; Chawengsub et al. 2009). Significantly, this transformation may require the presence of a CYP450 hemoprotein, operating though as a hydroperoxide isomerase rather than an epoxygenase (Chawengsub et al. 2009). Hence, given the great potential of the eicosanoid system, it is not too far-fetched to think that the putative oxygen messenger may derive from the concerted operation of 2 distinct AA pathways. But what is the actual evidence in support of this concept? So far, 2 facts may be brought to bear. It has been shown that 12-HETE, with either “R” or “S” configuration, may serve as a substrate for epoxygenase (Jajoo et al. 1992; J.R. Falck, personal communication). Furthermore, CYP3A hemoproteins, which are not regarded as prime catalytic elements for fatty acid epoxidation, are still able to function as an AA epoxygenase (Ayajiki et al. 2003). Future work will build on this information and provide guidance towards the ultimate characterization.

Acknowledgements

This work was supported by a grant of the Italian Ministry of Education and Research (PRIN 2007E7Y7R).

References


